Pharmaceutical News

RSS

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

...

23 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

The Christian Doppler Laboratory for Biosimilar Characterization is now open at the Paris-Lodron University of Salzburg, and scientists there have commenced developing new methods for characterizing proteins to be used in biopharmaceuticals.

23 Oct 2013

FDA alerts on voluntary recall of sterile use products from Specialty Compounding

The U.S. Food and Drug Administration is alerting hospitals, health care providers, veterinarians, and patients of a voluntary recall of certain human and veterinary products produced and distributed for sterile use by Specialty Medicine Compounding Pharmacy of South Lyon, Mich.

23 Oct 2013

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

23 Oct 2013

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.

23 Oct 2013

Flu vaccine may also reduce risk of heart attack by 50% among people who had heart attack

The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.

23 Oct 2013

Influenza vaccination linked with reduced risk of adverse cardiovascular events

Receiving an influenza vaccination was associated with a lower risk of major adverse cardiovascular events such as heart failure or hospitalization for heart attack, with the greatest treatment effect seen among patients with recent acute coronary syndrome (ACS; such as heart attack or unstable angina), according to a meta-analysis published in the October 23/30 issue of JAMA.

23 Oct 2013

Study examines association between suicidal vulnerability and analgesic consumption in elderly

A paper published in the current issue of Psychotherapy and Psychosomatics has investigated the relationship between pain killers and suicidal behavior in the elderly.

23 Oct 2013

FDA issues final approval for Lupin's sNDA for Antara capsules

Pharma Major Lupin Limited announced today that it has received final approval for its supplemental New Drug Application for Antara (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration.

23 Oct 2013

CoLucid signs distribution and supply agreement with ILDONG for Lasmiditan

CoLucid Pharmaceuticals, Inc., and ILDONG Pharmaceutical Co., Ltd., announced today that they have entered into a distribution and supply agreement for Lasmiditan in South Korea and Southeast Asia.

23 Oct 2013

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Pfizer to continue development of Remoxy Extended-Release Capsules CII

Pfizer Inc. announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy (oxycodone) Extended-Release Capsules CII.

22 Oct 2013

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Aduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for CRS-207, a novel immunotherapy, for the treatment of pancreatic cancer.

22 Oct 2013

InnoCore, Allergan expand collaboration to develop ophthalmology medicines

InnoCore Pharmaceuticals today announced that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc., a multi-specialty health care company headquartered in Irvine, California.

22 Oct 2013

COPD treatments: an interview with Professor Price, University of Aberdeen

The first thing is that we can’t cure COPD. The problem we have with COPD is that the process itself is not treatable, certainly not once it gets to the extent that it’s advanced.

22 Oct 2013

Capsugel launches Coni-Snap sprinkle capsule for people with difficulties swallowing

Capsugel is launching an innovative capsule design to improve adherence to treatment regimens for patients with difficulties swallowing. These patients include babies, children, and older adults as well as patients with medical conditions such as Alzheimer's, Parkinson's, and Multiple Sclerosis. The new Coni-Snap sprinkle capsule is expected to be available in 2014.

22 Oct 2013

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology.

22 Oct 2013

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

NeuroAiD™, a treatment of post-stroke recovery containing natural extracts, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months after stroke onset, without an increase in bleeding rate and non-vascular deaths according to research published online in the journal Stroke.

22 Oct 2013

Pharmaceutical News

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

FDA alerts on voluntary recall of sterile use products from Specialty Compounding

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Flu vaccine may also reduce risk of heart attack by 50% among people who had heart attack

Influenza vaccination linked with reduced risk of adverse cardiovascular events

Study examines association between suicidal vulnerability and analgesic consumption in elderly

FDA issues final approval for Lupin's sNDA for Antara capsules

CoLucid signs distribution and supply agreement with ILDONG for Lasmiditan

Novozymes Biopharma partners with Almac to provide combined service for drug development

Pfizer to continue development of Remoxy Extended-Release Capsules CII

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

InnoCore, Allergan expand collaboration to develop ophthalmology medicines

COPD treatments: an interview with Professor Price, University of Aberdeen

Capsugel launches Coni-Snap sprinkle capsule for people with difficulties swallowing

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News